試す - 無料

New Zealand MedTech Guns for Global Reach

BioSpectrum Asia

|

BioSpectrum Asia Feb 2024

New Zealand's medical technology industry is experiencing rapid growth. In 2022, the Technology Investment Network (TIN) reported that 17 MedTech companies ranked among the country's top 200 technology firms. A mix of established and emerging innovators is addressing challenging issues, from innovative surgical techniques to Al-driven micro-implantable devices. This transformation is fuelled by substantial support from both the government and private sector. Let's delve into the details of New Zealand's thriving MedTech ecosystem.

New Zealand MedTech Guns for Global Reach

From a burgeoning industry with a handful of homegrown companies to a powerhouse boasting over 200 players, the New Zealand MedTech sector is booming and the sector is worth around $2.1 billion, according to Uniservices.

New Zealand aims to be the leader in the MedTech space and has announced various initiatives and programmes to that extent.

"The New Zealand Government supports and invests in a range of projects, partnerships and programmes across the science, innovation and technology system," said Danette

MedTech-1Q Aotearoa, a national innovation collaboration, aims to accelerate the success of the New Zealand MedTech sector. It's a 'world-first' initiative targetting the $815 billion global medical device and digital health market. This virtual hub, linked to physical hubs in Auckland, Wellington, Christchurch, and Dunedin, employs a strategic, country-wide approach to enhance New Zealand's economic and physical health outcomes through MedTech collaboration and innovation. Deloitte Access Economics estimates a $1.5 billion increase in NZ's GDP by 2050 through MedTech-iQ.

In October 2021, the government announced an investment of $8.1 million over three years in Te Titoki Mataora, the MedTech Research Translator. The 18-month-old (as of April 2023) programme has already awarded $2.27 million in early seed funding to 40 projects nationwide.

"Government-funded MedTech initiatives include the Te Titoki Mataora (TTM) MedTech Research Translator, which is hosted by the Auckland Bioengineering Institute (ABI) on behalf of the Consortium for Medical Device Technologies – a collaborative partnership between the University of Auckland, University of Otago, University of Canterbury and Callaghan Innovation. This deep tech research translator focuses on the translation of research that addresses healthcare needs and improves the equity of access to care and outcomes,” said Danette Olsen.

BioSpectrum Asia からのその他のストーリー

BioSpectrum Asia

BioSpectrum Asia

India signs MoU with Pfizer to strengthen healthcare innovation ecosystem

In a significant step towards strengthening India's healthcare innovation ecosystem, the Department for Promotion of Industry and Internal Trade (DPIIT), Ministry of Commerce and Industry, Government of India, has signed a Memorandum of Understanding (MoU) with US-based Pfizer Limited.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

New Zealand to lead new gene therapy trial for muscular dystrophy

The first clinical trial of a new treatment for a rare form of muscular dystrophy is being led by New Zealand-based University of Auckland's Centre for Brain Research.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

Scientists in Australia grow living skin in world-first

Australia's University of Queensland (UQ) researchers have been the first in the world to successfully grow fully functioning human skin in a laboratory.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

India joins Health AI Global Regulatory Network to strengthen oversight of AI in healthcare

HealthAI - The Global Agency for Responsible AI in Health, has welcomed India as a pioneer country joining the HealthAI Global Regulatory Network (GRN), a global network of health regulators dedicated to the safe and effective use of artificial intelligence (AI) in healthcare.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

TVM Capital Healthcare announces first closing of $150 M Southeast Asia Fund

Singapore-based TVM Capital Healthcare, a global private equity investor and operator specialised in healthcare growth capital across emerging markets, has announced the first closing of its $150 million TVM Healthcare Southeast Asia Fund (SEA Fund).

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

National Yang Ming Chiao Tung University, TSH Biopharm collaborate to foster pharma talent in Taiwan

Taiwan's National Yang Ming Chiao Tung University (NYCU) and TSH Biopharm have signed a five-year industry-academia collaboration Memorandum of Understanding (MOU).

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

Fujifilm Biosciences introduces BalanCD HEK293 Perfusion A Medium

Fujifilm Biosciences, a global leader in the innovation and manufacture of cell culture solutions for the life science market, has announced the commercial launch of BalanCD HEK293 Perfusion A.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

Korea makes smart patch that can run tests using sweat instead of blood

A research team at Korea Advanced Institute of Science and Technology has developed a smart patch that can precisely observe internal changes through sweat when simply attached to the body.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

ADB approves $106.9 M to strengthen secondary healthcare services in Sri Lanka

The Asian Development Bank (ADB) has approved a $106.9 million financing package to strengthen Sri Lanka's secondary curative care services, improve communicable disease prevention and control, and enhance the healthcare sector's governance and management capacity.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

Epigenic Therapeutics raises $60 M to accelerate clinical development of medicines

China-based startup Epigenic Therapeutics, a clinical-stage innovative drug development company, has announced the completion of a $60 million Series B round of financing led by Lapam Capital, with continued participation from existing investors Qiming Venture Partners and OrbiMed, and addition of new investors including IFSC and a renowned investment firm in the industry.

time to read

1 min

BioSpectrum Asia Oct 2025

Listen

Translate

Share

-
+

Change font size